Alqahtani T, Alsubait A, Aloumi M, Alamer A, Alomari G, Alwassil O
BMC Cancer. 2024; 24(1):1569.
PMID: 39716145
PMC: 11665027.
DOI: 10.1186/s12885-024-13345-9.
Carlos Montero J, Tur R, Jimenez-Perez A, Filipovich E, Alcaraz S, Rodriguez M
Int J Mol Sci. 2024; 25(23).
PMID: 39684377
PMC: 11641570.
DOI: 10.3390/ijms252312665.
Clifton-Bligh R
Endocr Relat Cancer. 2024; 32(2).
PMID: 39655713
PMC: 11798414.
DOI: 10.1530/ERC-24-0224.
Luciano N, Orlandella F, Braile M, Cavaliere C, Aiello M, Franzese M
J Transl Med. 2024; 22(1):1088.
PMID: 39616372
PMC: 11608493.
DOI: 10.1186/s12967-024-05896-z.
Di Grazia G, Conti C, Nucera S, Motta G, Martorana F, Stella S
Front Oncol. 2024; 14:1427228.
PMID: 39211557
PMC: 11358597.
DOI: 10.3389/fonc.2024.1427228.
The rapidly changing field of predictive biomarkers of non-small cell lung cancer.
Toth L, Mokanszki A, Mehes G
Pathol Oncol Res. 2024; 30:1611733.
PMID: 38953007
PMC: 11215025.
DOI: 10.3389/pore.2024.1611733.
Oncofusions - shaping cancer care.
Dashi G, Varjosalo M
Oncologist. 2024; 30(1).
PMID: 38833619
PMC: 11783282.
DOI: 10.1093/oncolo/oyae126.
Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer.
Zhang W, Lin S, Wang Z, Zhang W, Xing M
J Clin Endocrinol Metab. 2024; 109(12):3166-3175.
PMID: 38735658
PMC: 11570377.
DOI: 10.1210/clinem/dgae327.
LncRNA GAS8-AS1 dinucleotide genetic variant is associated with early-stage disease, lymph node, and distant metastasis in differentiated thyroid cancer.
Murugan A, Al-Hindi H, Alzahrani A
Endocrine. 2024; 85(3):1278-1288.
PMID: 38580894
DOI: 10.1007/s12020-024-03802-7.
RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report.
Pishdad R, Illei P, Gocke C, Ball D
Front Oncol. 2024; 14:1360492.
PMID: 38469239
PMC: 10926684.
DOI: 10.3389/fonc.2024.1360492.
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.
Chen W, Dream S, Leung P, Wu P, Wong S, Park J
NPJ Precis Oncol. 2024; 8(1):39.
PMID: 38378752
PMC: 10879150.
DOI: 10.1038/s41698-024-00536-7.
RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis.
Bulanova Pekova B, Sykorova V, Mastnikova K, Vaclavikova E, Moravcova J, Vlcek P
Endocr Relat Cancer. 2023; 30(12).
PMID: 37882481
PMC: 10620462.
DOI: 10.1530/ERC-23-0117.
Progress in Thyroid Cancer Genomics: A 40-Year Journey.
Fagin J, Nikiforov Y
Thyroid. 2023; 33(11):1271-1286.
PMID: 37668657
PMC: 10664575.
DOI: 10.1089/thy.2023.0045.
Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.
Ju G, Sun Y, Wang H, Zhang X, Mu Z, Sun D
J Clin Endocrinol Metab. 2023; 109(2):505-515.
PMID: 37622214
PMC: 10795910.
DOI: 10.1210/clinem/dgad500.
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Steen E, Basilaia M, Kim W, Getz T, Gustafson J, Zage P
Biochem Pharmacol. 2023; 216:115751.
PMID: 37595672
PMC: 10911250.
DOI: 10.1016/j.bcp.2023.115751.
deficiency decreases neural crest progenitor proliferation and restricts fate potential during enteric nervous system development.
Vincent E, Chatterjee S, Cannon G, Auer D, Ross H, Chakravarti A
Proc Natl Acad Sci U S A. 2023; 120(34):e2211986120.
PMID: 37585461
PMC: 10451519.
DOI: 10.1073/pnas.2211986120.
Using CRISPR/Cas9 to Edit a Thyroid Cancer Cell Line.
Fuziwara C, Kimura E
Adv Exp Med Biol. 2023; 1429:73-84.
PMID: 37486517
DOI: 10.1007/978-3-031-33325-5_5.
Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
Staubitz J, Muller C, Heymans A, Merten C, Roos B, Poplawski A
BJS Open. 2023; 7(3).
PMID: 37146205
PMC: 10162683.
DOI: 10.1093/bjsopen/zrad029.
Molecular and clinical features of papillary thyroid cancer in adult patients with a non-classical phenotype.
Zhou J, Wang W, Zhang H, Gao Q, Wang W, Zhu J
Front Endocrinol (Lausanne). 2023; 14:1138100.
PMID: 37124750
PMC: 10130378.
DOI: 10.3389/fendo.2023.1138100.
RET signaling in breast cancer therapeutic resistance and metastasis.
Pecar G, Liu S, Hooda J, Atkinson J, Oesterreich S, Lee A
Breast Cancer Res. 2023; 25(1):26.
PMID: 36918928
PMC: 10015789.
DOI: 10.1186/s13058-023-01622-7.